Lexicon Pharmaceuticals Inc. (LXRX): What Does Valuation Ratios Tell Us?

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) saw an upside of 6.43% to close Tuesday at $6.12 after adding $0.37 on the day. The 5-day average trading volume is 1,241,160 shares of the company’s common stock. It has gained $6.18 in the past week. An average of 849,995 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,005,096.

LXRX’s 1-month performance is 32.75% or $1.46 on its low of $4.40 reached on 09/16/21. The company’s shares have touched a 52-week low of $1.03 and high of $9.65, with the stock’s rally to the 52-week high happening on 02/02/21. YTD, LXRX has achieved 78.95% or $2.70. However, the current price is down -36.58%% from the 52-week high price.

A Backdoor Way To Profit From Today’s Crypto Bull Market

In any crypto bull market, there's a lot of money to be made.

But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?

This strategy is simply and ridiculously easy.

Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.


Insider Transactions

On Mar 15, 212 days have gone by since the last insider trading activity for Lexicon Pharmaceuticals Inc. (LXRX). Tessmer James F (VP, Finance & Accounting) most recently sold 22,912 shares at $6.92 per share on Mar 15. This transaction cost the insider $158,440.

Valuation Metrics

The company’s PE ratio for the last five years has touched a high of 15.69 and a low of 1.731. LXRX stock has a beta of 1.42. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 124.08 while the price-to-book (PB) in the most recent quarter is 6.44.

As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.09. In terms of profitability, the gross margin trailing 12 months is 91.10%. The trailing 12-month EBITDA margin is -709.94%. The firm’s gross profit as reported stood at $22.07 million against revenue of $24.0 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Lexicon Pharmaceuticals Inc.’s cash and short-term investments amounted to $28.61 million against total debt of $14.32 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected LXRX to announce -$0.16 per share in earnings in its latest quarter, but it posted -$0.13, representing a 18.80% surprise. EBITDA for the quarter stood at more than -$17.9 million. LXRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 34.44 million, with total debt at $14.32 million. Shareholders hold equity totaling $144.47 million

Technical Picture

Let’s look briefly at Lexicon Pharmaceuticals Inc. (LXRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 80.92% to suggest the stock is trending Overbought, with historical volatility in this time period at 56.73%.

The stock’s 5-day moving average is $5.68, reflecting a +26.19% or $1.27 change from its current price. LXRX is currently trading +37.22% above its 20-day SMA, +40.69% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +67.67% and +75.36% respectively.

Stochastic %K and %D was 87.46% and 88.63% and the average true range (ATR) pointed at 0.33. The RSI (14) points at 75.12%, while the 14-day stochastic is at 96.01% with the period’s ATR at 0.31. The stock’s 9-day MACD Oscillator is pointing at 0.52 and 0.60 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), JP Morgan upgraded it to a Neutral rating. They previously had an Underweight rating on the stock. Analysts offering their rating for LXRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate LXRX as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.

What is LXRX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $6.00 and a high of $20.00, with their median price target at $13.00. Looking at these predictions, the average price target given by analysts is for Lexicon Pharmaceuticals Inc. (LXRX) stock is $13.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam